Sensus Healthcare To Sponsor First International Keloid Symposium On September 8 And 9 In New York
BOCA RATON, Fla., Aug. 31, 2016 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy (SRT), today announced that the Company will sponsor the First International Keloid Symposium to be held at The Rockefeller University in New York on Thursday, September 8th and Friday, September 9th.
The First International Keloid Symposium is a not for profit two day event organized to bring together industry doctors and scientists to provide a unique environment for collaboration on better practices in the diagnosis, prevention and treatment of keloid disease. Registered attendees consist of industry experts in basic science, dermatopathology, specialist clinicians with an interest in keloid scars from dermatology, plastic surgery, oncology, pediatric and general surgery, ENT, maxillofacial as well as specialist nurses, physiotherapists, occupational therapists and psychologists.
"We are thrilled to be the platinum sponsor of the First International Keloid Symposium being held at The Rockefeller University in New York City," said Joe Sardano, Chief Executive Officer for Sensus Healthcare. "Keloid disease is an underserved market which we have a keen interest in helping to address with our SRT devices. It is exciting to display our innovative technology in a unique environment of international thought leaders and practitioners in the industry."
Through its sponsorship program, the Symposium is also bringing products, services and devices (existing or in development) to display their solutions in front of leading industry professionals. The Symposium will emphasize both the scientific and clinical content across the breadth of keloid scars; highlighting cutting edge basic science research to pros and cons of current and newly emerging treatment approaches including surgical management, cryotherapy, electrotherapy, chemotherapy and other interventions.
For more information and registration, please visit the event website: keloidsymposium.com
About Sensus
Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100 and SRT-100 Vision. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit http://www.sensushealthcare.com.
Investor Relations:
Jeffrey Goldberger / Allison Soss
KCSA Strategic Communications
Phone: 212-896-1249 / 212-896-1267
Email: jgoldberger@kcsa.com / asoss@kcsa.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sensus-healthcare-to-sponsor-first-international-keloid-symposium-on-september-8-and-9-in-new-york-300320526.html
SOURCE Sensus Healthcare
